Castle biosciences stock.
Stock Info Stock Quote Price $19.88 Volume 52,546 Change +0.03 % Change +0.15% Today's Open $19.69 Previous Close $19.85 Intraday High $20.26 Intraday Low $19.69 52-Week High $29.59 52-Week Low $9.26 Pricing delayed by 20 minutes. Last Updated 11/24/2023 1:00 PM ET Stock Chart View stock chart as data table From: To:
Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.It’s estimated that there are over 30,000 castles in Ireland. Some are parts of ruins, some are homes, some are offices — and some castles in Ireland are available for people from all over the world to visit and stay in during their vacatio...About the Castle Biosciences, Inc. stock forecast. As of 2023 November 23, Thursday current price of CSTL stock is 19.810$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Castle Biosciences stock price has been showing a declining tendency so we believe that …Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.51 -0.27 (-1.37%) As of 03:38PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Max Full screen …Castle Biosciences, Inc. (CSTL) Stock Price | Stock Quote Nasdaq - MarketScreener CASTLE BIOSCIENCES, INC. PDF Report Castle Biosciences, Inc. Stock price …
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...
Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...10. HealthQuest Capital joined the board of directors in 2014. In 2014, Castle Biosciences landed $11.8 million during a financing round led by new investor HealthQuest Capital. In return for its contribution, Healthquest was given a place on the company’s board of directors.Whoopi Goldberg tested positive for Covid and will be absent from The View until she recovers. A day after it was confirmed she had fallen ill, the co-hosts of the ABC daytime talk show addressed ...
How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences …
The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical …
Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.The estimated net worth of David S. Kabakoff is at least $3.83 million as of June 22nd, 2020. Mr. Kabakoff owns 212,178 shares of Castle Biosciences stock worth more than $3,831,935 as of November 6th. This net worth evaluation does not reflect any other investments that Mr. Kabakoff may own. Learn More about David S. Kabakoff's net …Castle Biosciences’ technology approach objectively measures optimal combinations of epithelial, immune, and stromal processes in the context of tissue morphology to extract tissue profiles (information from digital whole side images of tissue biopsies) that are correlated with diagnosis and prognosis. Our tissue systems biology approach integrates …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.
52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...Nov 24, 2023Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ...The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...
Mar 20, 2023 · Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholders
Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...The estimated Net Worth of Mara G. Aspinall is at least $2.79 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,995,313 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Cathie Wood's Top 15 Small-Cap Stock Picks Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2022 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ: ...Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47. Apr 5, 2022 · AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...
On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...
Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...
Castle Biosciences, Inc. plans to launch a genomic test by the end of 2025 that can guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions. New data shows the test's ability to distinguish between responders and non-responders to an atopic dermatitis therapy, as well as …Find the latest Interpace Biosciences, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading and investing.Following this news, Relmada’s stock price fell nearly 80% to close at $6.48 per share on October 13, 2022. ... Castle Biosciences, Inc. (NASDAQ: CSTL)The estimated Net Worth of Bernhard E. Spiess is at least $7.14 Million dollars as of 10 December 2021. Mr. Spiess owns over 1,500 units of Castle Biosciences stock worth over $346,275 and over the last 4 years he sold CSTL stock worth over $6,796,778. In addition, he makes $0 as Chief Business Officer at Castle Biosciences.Jul 11, 2023 · Castle Biosciences makes tests for patients diagnosed with certain diseases to help evaluate optimal treatment options. Read my analysis of CSTL stock here. ... Castle stock had fallen to ~$33 per ... Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to …-15.00 Russell 2000 +11.96 -1.56 Gold Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.88 +0.03 (+0.15%) At close: 01:00PM EST 19.88 0.00...At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.On November 3, 2023, Castle Biosciences Inc (CSTL) stock is expected to experience positive growth, according to analysts. The 8 analysts offering 12-month price forecasts for CSTL have a median target of $32.50, with a high estimate of $40.00 and a low estimate of $25.00.Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …
Oct 25, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ... Castle Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall …November 22, 2023 at 3:28 AM · 2 min read. Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares ...Castle Biosciences has risen higher in 1 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 25%. Is Castle Biosciences Stock Undervalued? The current Castle Biosciences [ CSTL] share price is $19.99. The Score for CSTL is 73, which is 46% above its historic median score of 50, and infers lower risk ...Instagram:https://instagram. nee stock newsmullins stockshort term bond yieldsbest stock trading courses Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. options calculatorback stock Castle Biosciences today announced it has signed a definitive agreement to acquire Cernostics, Inc. ... which may consist entirely of cash or $20 million in cash and $10 million in common stock of ... how to calculate dividend yield Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, was $(6.9) million ...AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...